Supporting Information

Transcription

1 Supporting Information In silico QT and APD Prolongation Assay for Early Screening of Drug-induced Proarrhythmic Risk Lucia Romero a, Jordi Cano a, Julio Gomis-Tena a, Beatriz Trenor a, Ferran Sanz b, Manuel Pastor b, Javier Saiz a * a Centro de Investigación e Innovación en Bioingeniería (CI 2 B), Universitat Politècnica de València, camino de Vera, s/n, Valencia, Spain. b Research Programme on Biomedical Informatics (GRIB), Institut Hospital del Mar d Investigacions Mèdiques (IMIM), Department. of Experimental and Health Sciences, Universitat Pompeu Fabra, carrer del Dr. Aiguader, 88, Barcelona, Spain. *Corresponding Author jsaiz@ci2b.upv.es 1

2 2

3 Table S1. Drug parameters and references. Name (1 st column), torsadogenic risk (2nd column and color coded background of first column: red (Class 1), orange (Class 2), bright green (Class 3) and dark green (Class 4)), pic 50 values for herg, I Ks and I CaL (3 rd to 5 th column), the EFTPC (6 th column) and references for the pic 50 values for herg, I Ks and I CaL (7 th to 9 th column), the EFTPC (10 th column). A dash in the IC 50 boxes means that no value was found in public databases neither in the scientific literature. 10 th to 14 th correspond to parameters found in given sources (see table header) and used to calculate EFTPC values. EFTPC values (in nm) calculated as follows: 10 1 where MC is the concentration of the drug in g.l 1 and MW is the molecular weight of the compound in g.mol 1. Drug values and s used as the highest value of available ranges, mean + SD or directly from the highest dosage regimen. Protein Bound Fraction and of the drugs belong to Drugbank.ca. Fraction ( ) (nm) (nm) Ref. Ikr Ref. Iks Ref. ICaL Ref. Ajmaline [15] - - [15] Amiodarone Astemizole , , , , [11], , , , , , , , , , , , , , [15] druginfo.cfm?setid=b0eb6c e3f-a06d-20a186ced99a [12] μg/ml 3

4 Bepridil Chlorpromazine values and s used as the highest value of available ranges, mean + SD or directly from the highest dosage regimen. Protein Bound Fraction and of the drugs belong to Drugbank.ca. (nm) Ref. Ikr Ref. Iks Ref. ICaL Ref. Fraction ( ) (nm) , , , , , Tie 2000/Tie , , , [15], Cilostazol [12] [12] [12] Cisapride , , , , , , , , , , , , , , , Lacerda 2001, , , , , , , , , 4 [15] [14] [12] [15] [13] , tfda_docs/label/2015/020863s023lbl.p df [15] ng/ml

5 Clarithromycin Disopyramide Dofetilide values and s used as the highest value of available ranges, mean + SD or directly from the highest dosage regimen. Protein Bound Fraction and of the drugs belong to Drugbank.ca. Fraction ( ) (nm) (nm) Ref. Ikr Ref. Iks Ref. ICaL Ref , , , , , , , , , Yamazaki , , , [19], , , , , , , , , , , Frederiksen 2001, , , , , , Lacerda 2001, , , , , [16], , , , , , , - - [19] [19] d/druginfo.cfm?setid=8a56f36f-4e45-43f6-842b-5c2d319aaaec druginfo.cfm?setid=11a68e26-d2e4-48f6-ba0f-9bdd5778f25a [15] μg/ml μg/ml

6 values and s used as the highest value of available ranges, mean + SD or directly from the highest dosage regimen. Protein Bound Fraction and of the drugs belong to Drugbank.ca. Fraction ( ) (nm) (nm) Ref. Ikr Ref. Iks Ref. ICaL Ref , , , , Domperidone , Donepezil [12] - [12] - - [2] ng/ml druginfo.cfm?setid=11ac01f4-d26e- 47b d514ab097fdb Dronedarone , [7] [7] pound/208898#section=absorption- Distribution-and-Excretion ng/ml Droperidol [12] - [12] [12] Flecainide [12] - [12] druginfo.cfm?setid= e6a0-6b7a-f428-9ca03d μg/ml Halofantrine [12] - [12] [12] Haloperidol , , , , , , , , , Frederiksen 2001, , , [12] - [15] [15] Ibutilide [12] - [12] pound/60753#section=absorption- Distribution-and-Excretion ng/ml Levofloxacin , , druginfo.cfm?setid=8962eb eec-44f9-170e686d2d μg/ml Methadone [12] - [12] [12] 6

7 Moxifloxacin values and s used as the highest value of available ranges, mean + SD or directly from the highest dosage regimen. Protein Bound Fraction and of the drugs belong to Drugbank.ca. (nm) Ref. Ikr Ref. Iks Ref. ICaL Ref. Fraction ( ) (nm) , , Thomsen 2006, , , , , , , , [16] [16], Okada 2015 Ondansetron druginfo.cfm?setid=71b02da db8-192a-c0a8a6cd98a5 druginfo.cfm?setid=2edc0788-dc38-4d21-ba8e-71f159e2d3b mg/l ng/ml Procainamide [12] - [12] druginfo.cfm?setid=17e47845-daad- 434c-a784-6d3875b0d μg/ml Quinidine , , , , , , , , , , Wang, , , , , , , , , , , , , [15], druginfo.cfm?setid=11d f69-4c30-b487-5d05f6462bd

8 values and s used as the highest value of available ranges, mean + SD or directly from the highest dosage regimen. Protein Bound Fraction and of the drugs belong to Drugbank.ca. Fraction ( ) (nm) (nm) Ref. Ikr Ref. Iks Ref. ICaL Ref , Sotalol , , , Wang, , , , Danda Hilal-Dandan, Laurence L. Brunton, Goodman & Gilman's Manual of Pharmacology and Therapeutics 2nd Edition, McGrawHill. P Sparfloxacin [12] - [12] [12] Tedisamil [15] [15] Terfenadine , , , , , , , , , Helson 2012, , Lacerda 2001, , , , , , [13] , [15], [12]

9 Terodiline Thioridazine Clozapine values and s used as the highest value of available ranges, mean + SD or directly from the highest dosage regimen. Protein Bound Fraction and of the drugs belong to Drugbank.ca. Fraction ( ) (nm) (nm) Ref. Ikr Ref. Iks Ref. ICaL Ref , , , , , , Tie 2000/Tie 2002, , , , , , , Frederiksen 2001, , Tie 2002 [6] [6] [10] , [12] [15], [15] druginfo.cfm?setid=d5c8a456-6f3c b321-4ed746f690e4 Dasatinib [16] [16] [16] [16] ng/ml Lapatinib [16] [16] [16] druginfo.cfm?setid=63319b01-cad6-4d0a-c39b-938fa951a μg/ml Nilotinib [16] [16] [16] [8] Ofloxacin d/druginfo.cfm?setid=1d19a6db- 6da5-e7de-f929-2d18bdfa2cf μg/ml Paliperidone [16] [16] [16] druginfo.cfm?setid=9089db76-aa50-417d-bf df161e9a ng/ml Risperidone , , , [13] , [15] [18] 9

10 values and s used as the highest value of available ranges, mean + SD or directly from the highest dosage regimen. Protein Bound Fraction and of the drugs belong to Drugbank.ca. Fraction ( ) (nm) (nm) Ref. Ikr Ref. Iks Ref. ICaL Ref , Saquinavir [12] - [12] druginfo.cfm?setid=c00d1607-ac36-457b-a34b-75ad74f9cf0a μg/ml Sunitinib [16] [16] [16] druginfo.cfm?setid=43a4d7f8-48ae- 4a fa8e3ea9d9c ng/ml Tolterodine [16] [16] [16] druginfo.cfm?setid=2cad3579-d ae b6a8d ng/ml Metronidazole [12] - [12] druginfo.cfm?setid=a c99-45a5-829b-ae8b189cbfd4 Nelfinavir [16] [16] [16] pound/64142#section=pharmacologyand-biochemistry μg/ml Paroxetine [12] - [12] tfda_docs/label/2014/020031s071, s035lbl.pdf ng/ml Quetiapine Ranolazine , , , , [15] [9] ng/ml Solifenacin [16] [16] [16] Voriconazole [12] - [12] druginfo.cfm?setid=8d442b8c-97a8-40a f9cd0542cedc tfda_docs/label/2013/021518s016lbl.p df tfda_docs/label/2015/021266s038, s047,021630s028lbl.pdf ng/ml ng/ml μg/ml Alvimopan [16] [16] [16] druginfo.cfm?setid=77a67dc6-35d3-48ff-9d18-292d4d442f ng/ml Ambrisentan [16] [16] [16] [8] Ceftriaxone [12] - [12] druginfo.cfm?setid=2dd1be9e-74cc- 48e8-bf02-f34a78d80fda μg/ml

11 values and s used as the highest value of available ranges, mean + SD or directly from the highest dosage regimen. Protein Bound Fraction and of the drugs belong to Drugbank.ca. Fraction ( ) (nm) (nm) Ref. Ikr Ref. Iks Ref. ICaL Ref. Darifenacin [16] [16] [16] [8] Darunavir [16] [16] [16] [8] Deferasirox [16] [16] [16] [8] Desvenlafaxine [16] [16] [16] [16] Diazepam [12] - [12] [12] Diltiazem [12] - [12] druginfo.cfm?setid=d6a81f9f-3a51-4e86-aeb b ng/ml Doxorubicin pound/31703#section=absorption- Distribution-and-Excretion μg/ml Duloxetine [12] [16] [12] [4] ng/ml Ebastine , [3] ng/ml Eltrombopag [16] [16] [16] druginfo.cfm?setid=616224ff-a925-4b38-9ca2-00fbf669380f Etravirine [16] [16] [16] [8] μg/ml Everolimus [16] [16] [16] druginfo.cfm?setid=e082a b-a5c2-2a a ng/ml Lamivudine [12] - [12] pound/60825#section=absorption- Distribution-and-Excretion μg/ml Lamotrigine [16] [16] [16] [8] Linezolid [12] - [12] tfda_docs/label/2015/021130s030, s029,021132s034lbl.pdf mg/l Loratadine [12] - [12] [12] Maraviroc [16] [16] [16] druginfo.cfm?setid=a94a9a2b-337b- 4c fc392194dc ng/ml Mibefradil [12] [12] [12] Mitoxantrone [12] - [12] [12] Nebivolol [16] [16] [16] [8] Nifedipine , , , , , 11 [5] ng/ml

12 values and s used as the highest value of available ranges, mean + SD or directly from the highest dosage regimen. Protein Bound Fraction and of the drugs belong to Drugbank.ca. Fraction ( ) (nm) (nm) Ref. Ikr Ref. Iks Ref. ICaL Ref , Nisoldipine [17] [17] [17], Palonosetron [16] [16] [16] [1] ng/ml druginfo.cfm?setid=bd06f321-bb f3-d59626b540e ng/ml Pentobarbital [12] [12] [12] Phenytoin [12] [12] druginfo.cfm?setid=78b38e7b adc-b ffa6259c μg/ml Propranolol , , , [15] druginfo.cfm?setid=2d9d9660-ef3a- 4abf-c291-db8d844ff658 Raltegravir [12] [16] [12] [12] ng/ml Ribavirin [12] - [12] druginfo.cfm?setid=35f99f76-f2ef- 4a81-91ff be ng/ml Sildenafil [16] [16] [16] [8] Silodosin [16] [16] [16] druginfo.cfm?setid=a21163d6-e1b bce3-751e c ng/ml Sitagliptin [12] [16] [12] druginfo.cfm?setid=f85a48d c50-b0fa-7673a160bf S-oxybutynin [11] druginfo.cfm?setid=c5950dba-d92b- 46a0-993f-af9f9ddb52bf ng/ml Tadalafil [16] [16] [16] druginfo.cfm?setid=ebddb745-81f9-4b b ed ng/ml Telbivudine [16] [16] [16] druginfo.cfm?setid= d a63-ba5f-4b899cdf3bec μg/ml 12

13 References. 1. Baksi, A. K.; Edwards, J. S.; Ahr, G. A Comparison of the Pharmacokinetics of Nisoldipine in Elderly and Young Subjects. Br. J. Clin. Pharmacol. 1991, 31 (3), Boyce, M. J.; Baisley, K. J.; Warrington, S. J. Pharmacokinetic Interaction between Domperidone and Ketoconazole Leads to QT Prolongation in Healthy Volunteers: A Randomized, Placebo-Controlled, Double-Blind, Crossover Study. Br. J. Clin. Pharmacol. 2012, 73 (3), Chaikin, P.; Gillen, M. S.; Malik, M.; Pentikis, H.; Rhodes, G. R.; Roberts, D. J. Co-Administration of Ketoconazole with H1-Antagonists Ebastine and Loratadine in Healthy Subjects: Pharmacokinetic and Pharmacodynamic Effects. Br. J. Clin. Pharmacol. 2005, 59 (3), Chan, C.; Yeo, K. P.; Pan, A. X.; Lim, M.; Knadler, M. P.; Small, D. S. Duloxetine Pharmacokinetics Are Similar in Japanese and Caucasian Subjects. Br. J. Clin. Pharmacol. 2007, 63 (3), Edwards, C.; Monkman, S.; Cholerton, S.; Rawlins, M. D.; Idle, J. R.; Ferner, R. E. Lack of Effect of Co-Trimoxazole on the Pharmacokinetics and Pharmacodynamics of Nifedipine. Br. J. Clin. Pharmacol. 1990, 30 (6), Shuba, L. M.; Kasamaki, Y.; Jones, S. E.; Ogura, T.; McCullough, J. R.; McDonald, T. F. Action Potentials, Contraction, and Membrane Currents in Guinea Pig Ventricular Preparations Treated with the Antispasmodic Agent Terodiline. J. Pharmacol. Exp. Ther. 1999, 290 (3), Gautier, P.; Guillemare, E.; Marion, A.; Bertrand, J.-P.; Tourneur, Y.; Nisato, D. Electrophysiologic Characterization of Dronedarone in Guinea Pig Ventricular Cells. J. Cardiovasc. Pharmacol. 2003, 41 (2), Gintant, G. An Evaluation of herg Current Assay Performance: Translating Preclinical Safety Studies to Clinical QT Prolongation. Pharmacol. Ther. 2011, 129 (2), Grimm, S. W.; Richtand, N. M.; Winter, H. R.; Stams, K. R.; Reele, S. B. Effects of Cytochrome P450 3A Modulators Ketoconazole and Carbamazepine on Quetiapine Pharmacokinetics. Br. J. Clin. Pharmacol. 2006, 61 (1), Hallén, B.; Karlsson, M. O.; Stromberg, S.; Norén, B. Bioavailability and Disposition of Terodiline in Man. J. Pharm. Sci. 1994, 83 (9), Jones, S. E.; Shuba, L. M.; Zhabyeyev, P.; McCullough, J. R.; McDonald, T. F. Differences in the Effects of Urinary Incontinence Agents S-Oxybutynin and Terodiline on Cardiac K(+) Currents and Action Potentials. Br. J. Pharmacol. 2000, 131 (2), Kramer, J.; Obejero-Paz, C. A.; Myatt, G.; Kuryshev, Y. A.; Bruening-Wright, A.; Verducci, J. S.; Brown, A. M. MICE Models: Superior to the HERG Model in Predicting Torsade de Pointes. Sci. Rep. 2013, 3 (1), Lacerda, A. E.; Kramer, J.; Shen, K. Z.; Thomas, D.; Brown, a. M. Comparison of Block among Cloned Cardiac Potassium Channels by Non-Antiarrhythmic Drugs. Eur. Hear. J. Suppl. 2001, 3 (Supplement K), Lee, S.-Y.; Choi, S.-Y.; Youm, J. B.; Ho, W.-K.; Earm, Y. E.; Lee, C. O.; Jo, S.-H. Block of HERG Human K(+) Channel and IKr of Guinea Pig Cardiomyocytes by Chlorpromazine. J. Cardiovasc. Pharmacol. 2004, 43 (5), Mirams, G. R.; Cui, Y.; Sher, A.; Fink, M.; Cooper, J.; Heath, B. M.; McMahon, N. C.; Gavaghan, D. J.; Noble, D. Simulation of Multiple Ion Channel Block Provides Improved Early Prediction of Compounds Clinical Torsadogenic Risk. Cardiovasc. Res. 2011, 91 (1), Mirams, G. R.; Davies, M. R.; Brough, S. J.; Bridgland-Taylor, M. H.; Cui, Y.; Gavaghan, D. J.; Abi-Gerges, N. Prediction of Thorough QT Study Results Using Action Potential Simulations Based on Ion Channel Screens. J. Pharmacol. Toxicol. Methods 2014, 70 (3), Missan, S.; Zhabyeyev, P.; Dyachok, O.; Jones, S. E.; McDonald, T. F. Block of Cardiac Delayed-Rectifier and Inward-Rectifier K+ Currents by Nisoldipine. Br. J. Pharmacol. 2003, 140 (5), Okereke, C. S.; Kirby, L.; Kumar, D.; Cullen, E. I.; Pratt, R. D.; Hahne, W. A. Concurrent Administration of Donepezil HCl and Levodopa/carbidopa in Patients with Parkinson s Disease: Assessment of Pharmacokinetic Changes and Safety Following Multiple Oral Doses. Br. J. Clin. Pharmacol. 2004, 58 Suppl 1, Satoh, H. Comparative Actions of Cibenzoline and Disopyramide on I(Kr) and I(Ks) Currents in Rat Sino-Atrial Nodal Cells. Eur. J. Pharmacol. 2000, 407 (1 2),